Plant stanol esters in spreads have demonstrated efficacy in reducing serum cholesterol. The cost-effectiveness of plant stanol esters in the prevention of coronary heart disease, however, has remained unevaluated.
Design
A Bayesian modelling approach was applied to synthesize clinical evidence and evaluate the cost-effectiveness (€/quality-adjusted life years) of plant stanol esters in spread in the prevention of coronary heart disease based on published FINRISK and 4S risk functions.
Results
The regular use of plant stanol esters reduced total serum cholesterol by −0.362 mmol/l [95% credibility interval (CrI) −0.31 to −0.41]. The corresponding placebo-adjusted reduction attributable to stanol esters when combined with statin was −0.385 mmol/l (95% CrI −0.18 to −0.61). The cost-effectiveness estimations were assessed for men and women separately at four different initial ages at which the regular use of stanol esters was assumed to be started. The base case cost per quality-adjusted life years gained by using stanol esters regularly ranged from €7436 to €20 999 in men and from €34 327 to €112151 in women based on the initial starting age. According to uncertainty analysis, there is over a 90% probability that the use of plant stanol esters is cost-effective for men inclusively and for 60-year-old and older women assuming that decision-makers' maximum willingness to pay per quality-adjusted life year is €50000.
Conclusions
A recommendation that plant stanol ester-containing spreads be used as a part of daily diet replacing regular spread could be viewed as potentially cost-effective public health policy in the prevention of CHD in all adult men and in older age-groups of women with total serum cholesterol levels of 5 mmol/l or greater.
World Health Organization.The World Health Report 2003: Shaping the future.Geneva: World Health Organization; 2003.
2.
PetersenSPetoVRaynerMLealJLuengo-FernandezRGrayA.European cardiovascular disease statistics 2005.London: British Heart Foundation; 2005.
3.
KatanMBGrundySMJonesPLawMMiettinenTPaolettiR, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels.Mayo Clin Proc2003; 78:965–978.
4.
LawM.Plant sterol and stanol margarines and health.BMJ2000; 320:861–864.
5.
LawMRWaldNJThompsonSG.By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease?BMJ1994; 308:367–372.
6.
CaroJKlittichWMcGuireAFordINorrieJPettittD, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.BMJ1997; 315:1577–1582.
7.
CummingsSRRubinSMOsterG.The cost-effectiveness of counseling smokers to quit.JAMA1989; 261:75–79.
8.
LindgrenPFahlstadiusPHelleniusMLJonssonBde FaireU.Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm: a stochastic model of exercise and dietary advice.Prev Med2003; 36:403–409.
9.
HatziandreuEIKoplanJPWeinsteinMCCaspersenCJWarnerKE.A cost-effectiveness analysis of exercise as a health promotion activity.Am J Public Health1988; 78:1417–1421.
10.
SchmidCH.Using Bayesian inference to perform meta-analysis.Eval Health Prof2001; 24:165–189.
11.
SmithTCSpiegelhalterDJThomasA.Bayesian approaches to random-effects meta-analysis: a comparative study.Stat Med1995; 14:2685–2699.
12.
ThompsonSGHigginsJP.How should meta-regression analyses be undertaken and interpreted?.Stat Med2002; 21:1559–1573.
13.
CookJRYinDAlemaoEDrummondM.Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.Pharmacoeconomics2004; 22(Suppl 3):37–48.
14.
LaatikainenTTapanainenHAlfthanGSalminenISundvallJLeiviskäJ, et al. FINRISKI 2002. Tutkimus kroonisten kansantautien riskitekijöistä, niihin liittyvistä elintavoista, oireista, psykososiaalisista tekijöistä ja terveyspalvelujen käytöstä. Tutkimuksen toteutus ja tulokset 2. Taulukkoliite. Publications of the National Public Health Institute B7/2003.Helsinki: National Public Health Institute; 2003.
15.
LaatikainenTTapanainenHAlfthanGSalminenISundvallJLeiviskäJ, et al. FINRISKI 2002. Tutkimus kroonisten kansantautien riskitekijöistä, niihin liittyvistä elintavoista, oireista, psykososiaalisista tekijöistä ja terveyspalvelujen käytöstä. Tutkimuksen toteutus ja tulokset 1. Perusraportti. Publications of the National Public Health Institute B7/2003.Helsinki: National Public Health Institute; 2003.
16.
AromaaAKoskinenS, editors. Health and functional capacity in Finland. Baseline results of the Health 2000 health examination survey. Publications of National Public Health Institute B3/2002.Helsinki: National Public Health Institute; 2002.
17.
Statistics Finland.Causes of death 2001.Helsinki: Publications of Statistics Finland; 2002.
18.
National Public Health Institute.Cardiovascular Disease Register, statistical database. http://www.ktl.fi/cvdr/. [Accessed 24 June 2004]
19.
BhopalRFischbacherCVartiainenEUnwinNWhiteMAlbertiG.Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data.J Public Health (Oxf)2005; 27:93–100.
20.
JohannessonMJonssonBKjekshusJOlssonAGPedersenTRWedelH.Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.N Engl J Med1997; 336:332–336.
21.
HäkkinenUIdänpään-HeikkiläUKeskimäkiIRauhalaAKlaukkaTTeittoE.Akuutin sydäninfarktien hoitokäytäntöjen, kustannusten ja vaikuttavuuden vertailu. Stakes, Aiheita 9/2002.Helsinki: National Research and Development Centre for Welfare and Health (STAKES); 2002.
22.
National Agency for Medicines and the Social Insurance Institution.Finnish statistics on medicines 2002.Helsinki: National Agency for Medicines and the Social Insurance Institution (Kela); 2003.
OhinmaaASintonenH.Quality of life of finnish population measured by EuroQol. In: BadiaXHerdmanMSeguraA, editors. EuroQol Planery Meeting Discussion papers, 3-Planery Meeting 5 Oct 1996, Barcelona.Barcelona: Catalan Institute of Public Health; 1996. pp. 161–172.
25.
KattainenE.A longitudinal research of the coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients' health-related quality of life [PhD thesis].Kuopio: Kuopio University Publications. E. Social Sciences, University of Kuopio; 2004.
26.
National Institute for Clinical Excellence (NICE).Guide to the methods of technology appraisal.Oxford: Radcliff Medical Press; 2004.
27.
SpiegelhalterDJBestNG.Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.Stat Med2003; 22:3687–3709.
28.
CooperNJSuttonAJAbramsKRTurnerDWailooA.Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach.Health Econ2004; 13:203–226.
29.
SamsaGPReutterRAParmigianiGAncukiewiczMAbrahamsePLipscombJ, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke.J Clin Epidemiol1999; 52:259–271.
VanhanenHTBlomqvistSEhnholmCHyvonenMJauhiainenM.TorstilaI, et al. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment.J Lipid Res1993; 34:1535–1544.
32.
MiettinenTAVanhanenH.Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes.Atherosclerosis1994; 105:217–226.
33.
VanhanenHTKajanderJLehtovirtaHMiettinenTA.Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects.Clin Sci (Lond)1994; 87:61–67.
34.
PlatJMensinkRP.Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects.Atherosclerosis2000; 148:101–112.
35.
NiinikoskiHViikariJPalmuT.Cholesterol-lowering effect and sensory properties of sitostanol ester margarine in normocholesterolemic adults.Scand J Nutr1997; 41:9–12.
36.
HallikainenMAUusitupaMI.Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects.Am J Clin Nutr1999; 69:403–410.
37.
WeststrateJAMeijerGW.Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects.Eur J Clin Nutr1998; 52:334–343.
38.
HallikainenMASarkkinenESGyllingHErkkilaATUusitupaMI.Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet.Eur J Clin Nutr2000; 54:715–725.
39.
MiettinenTAPuskaPGyllingHVanhanenHVartiainenE.Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population.N Engl J Med1995; 333:1308–1312.
40.
GyllingHRadhakrishnanRMiettinenTA.Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol.Circulation1997; 96:4226–4231.
41.
HallikainenMASarkkinenESUusitupaMI.Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner.J Nutr2000; 130:767–776.
42.
JonesPJRaeini-SarjazMNtaniosFYVanstoneCAFengJYParsonsWE.Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters.J Lipid Res2000; 41:697–705.
43.
GyllingHMiettinenTA.Cholesterol reduction by different plant stanol mixtures and with variable fat intake.Metabolism1999; 48:575–580.
44.
NguyenTTDaleLCvon BergmannKCroghanIT.Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial.Mayo Clin Proc1999; 74:1198–1206.
45.
AnderssonAKarlströmBMohsenRVessbyB.Cholesterol-lowering effects of a stanol ester-containing low-fat margarine used in conjunction with a strict lipid-lowering diet.Eur Heart J Supplements1999; 1 (Suppl S):80–90.
46.
NoakesMCliftonPNtaniosFShrapnelWRecordIMcInerneyJ.An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations.Am J Clin Nutr2002; 75:79–86.
47.
GyllingHMiettinenTA.Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment.Diabetologia1994; 37:773–780.
48.
PlatJvan OnselenENvan HeugtenMMMensinkRP.Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters.Eur J Clin Nutr2000; 54:671–677.
49.
HommaYIkedaIIshikawaTTatenoMSuganoMNakamuraH.Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: a randomized, placebo-controlled trial.Nutrition2003; 19:369–374.
50.
VanhanenH.Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients.Eur J Clin Pharmacol1994; 47:169–176.
51.
GyllingHMiettinenTA.Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men.J Lipid Res1996; 37:1776–1785.
52.
BlairSNCapuzziDMGottliebSONguyenTMorganJMCaterNB.Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.Am J Cardiol2000; 86:46–52.
53.
GyllingHMiettinenTA.LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.Nutr Metab Cardiovasc Dis2002; 12:19–23.
54.
National Institute for Clinical Excellence (NICE).Expert opinion regarding experience with NICE in UK. http://www.nice.org.uk. [Accessed 22 August 2005]
55.
AvinsALBrownerWS.Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes.JAMA1998; 279:445–449.
56.
AnttolainenMLuotoRUutelaABoiceJDJrBlotWJMcLaughlinJK, et al. Characteristics of users and nonusers of plant stanol ester margarine in Finland: an approach to study functional foods.J Am Diet Assoc2001; 101:1365–1368.
57.
JousilahtiPVartiainenETuomilehtoJPuskaP.Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14786 middle-aged men and women in Finland.Circulation1999; 99:1165–1172.
58.
LuotoRSimojokiMUutelaABoiceJDJrMcLaughlinJKPuskaP.Consistency of use of plant stanol ester margarine in Finland.Public Health Nutr2004; 7:63–68.
59.
KromhoutD.Epidemiology of cardiovascular diseases in Europe.Public Health Nutr2001; 4:441–457.
60.
MorrisS.A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.Health Econ1997; 6:589–601.
61.
University of Oxford Health Economics Research Centre.Making difficult choices: decision making in health care. http://www.herc.ox.ac.uk/research/diff.shtml. [Accessed 1 December 2005]
